People: Achillion Pharmaceuticals Inc (ACHN.O)
20 Jan 2017
Dr. Milind S. Deshpande, Ph.D., is President, Chief Executive Officer, Director of the Company. Prior to that, he was our President of Research and Development and Chief Scientific Officer. Prior to joining Achillion in September 2001, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb, a pharmaceutical company, from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande is on the board of directors of Spero Therapeutics, a biotechnology company. Dr. Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India.
|Total Annual Compensation, USD||868,960|
|Restricted Stock Awards, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||4,078,780|
|Fiscal Year Total, USD||4,947,740|